Market news: The full Phase III study results published in the New England Journal of Medicine showed that Eli Lilly's (LLY.N) oral obesity drug Orforglipron showed convincing efficacy and safety, consistent with injectable GLP-1 drugs.
2025-06-21
Market news: The full Phase III study results published in the New England Journal of Medicine showed that Eli Lilly's (LLY.N) oral obesity drug Orforglipron showed convincing efficacy and safety, consistent with injectable GLP-1 drugs.